Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

pipeline, and anticipated milestones for 2025 and beyond at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT. Nimbus Therapeutics is a clinical-stage ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...

The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471 ...

HONOLULU, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Krilla Kaleiwahea LLC (K2), a Native Hawaiian Organization leader in defense, technology, resilience, and workforce development for the U.S. federal ...

Winners include Metsera, COUR Pharmaceuticals, Mirador and Seaport Therapeutics. "This year's NextGen class hits on all the hot areas, from GLP-1s in weight loss to ADCs in cancer and cell therapy in ...

Winners include Metsera, COUR Pharmaceuticals, Mirador and Seaport Therapeutics. "This year's NextGen class hits on all the hot areas, from GLP-1s in weight loss to ADCs in cancer and cell therapy ...